Pharmacokinetics, bioavailability, & bioequivalence Original research| Volume 34, ISSUE 7, P1613-1624, July 2012

Efficacy and Tolerability of Initial Therapy With Single-Pill Combination Telmisartan/Hydrochlorothiazide 80/25 mg in Patients With Grade 2 or 3 Hypertension: A Multinational, Randomized, Double-Blind, Active-Controlled Trial



      Patients with grade 2 or 3 hypertension may require high-dose combination therapy to achieve blood pressure (BP) targets in a timely manner.


      This study compared the effectiveness and tolerability of a single-pill combination (SPC) of telmisartan/hydrochlorothiazide 80/25 mg (T80/H25) with T80 monotherapy.


      In a Phase IV, multinational, randomized, double-blind, double-dummy, active-controlled, parallel-group trial, 894 patients with mean seated trough cuff systolic BP [SBP] ≥160 mm Hg and diastolic BP [DBP] ≥100 mm Hg were randomly assigned in a 2:1 ratio to receive T40/H12.5 SPC or telmisartan 40 mg monotherapy for 1 week before the dose was uptitrated to T80/H25 SPC or T80, respectively, administered for 6 weeks. The primary efficacy measure was the change from baseline in mean seated cuff trough SBP. Adverse events (AEs) were recorded.


      A total of 888 patients received treatment (294 and 594 patients in the T80/H25 and T80 groups, respectively) (mean age, 57.0 years; age ≥65 years, 25.7%; male, 53.8%; white, 68.0%); 61 patients prematurely discontinued. Mean baseline SBP/DBP values were 172.3/104.3 mm Hg (T80/H25) and 173.3/104.5 mm Hg (T80). After 7 weeks, SBP was changed by −37.0 and −28.5 mm Hg in the T80/H25 and T80 groups (P < 0.0001); DBP was changed by −18.6 and −15.4 mm Hg respectively (P < 0.0001). These differences were significant after 2 weeks at the higher dosage (P < 0.0001). BP target (SBP/DBP <140/<90 mm Hg) was achieved in 55.5% and 34.7% of patients in the T80/H25 and T80 groups (P < 0.0001). T80/H25 SPC and T80 had a similar frequency of overall AEs (16.0% vs 17.0%). The prevalences of treatment-related AEs with T80/H25 SPC and T80 were low (4.6% and 2.8%), as were the rates of AEs that led to discontinuation (1.0% and 2.8%).


      In these patients with grade 2 or 3 hypertension, initial therapy with T80/H25 was associated with a significantly greater reduction in mean seated cuff trough SBP compared with T80 alone, as well as with improved hypertension goal attainment rates. Both treatments appeared to be well tolerated. identifier: NCT00926289.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Chobanian A.V.
        • Bakris G.L.
        • Black H.R.
        • et al.
        Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.
        Hypertension. 2003; 42: 1206-1252
        • Mancia G.
        • De B.G.
        • Dominiczak A.
        • et al.
        • The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)
        2007 Guidelines for the management of arterial hypertension.
        J Hypertens. 2007; 25: 1105-1187
        • Zhang Y.
        • Zhang X.
        • Liu L.
        • Zanchetti A.
        Is a systolic blood pressure target <140 mmHg indicated in all hypertensives?.
        Eur Heart J. 2011; 32: 1500-1508
        • Ogihara T.
        • Kikuchi K.
        • Matsuoka H.
        • et al.
        The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2009).
        Hypertens Res. 2009; 32: 3-107
        • Writing group of 2010 Chinese guidelines for the management of hypertension
        2010 Chinese guidelines for the management of hypertension [in Chinese].
        Chin J Cardiol. 2011; 39: 579-616
        • Tedesco M.A.
        • Natale F.
        • Calabro R.
        Effects of monotherapy and combination therapy on blood pressure control and target organ damage: a randomized prospective intervention study in a large population of hypertensive patients.
        J Clin Hypertens (Greenwich). 2006; 8: 634-641
        • Wald D.S.
        • Law M.
        • Morris J.K.
        • et al.
        Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials.
        Am J Med. 2009; 122: 290-300
        • Littlejohn III, T.W.
        • Majul C.R.
        • Olvera R.
        • et al.
        Results of treatment with telmisartan-amlodipine in hypertensive patients.
        J Clin Hypertens (Greenwich). 2009; 11: 207-213
        • Littlejohn III, T.W.
        • Majul C.R.
        • Olvera R.
        • et al.
        Telmisartan plus amlodipine in patients with moderate or severe hypertension: results from a subgroup analysis of a randomized, placebo-controlled, parallel-group, 4 × 4 factorial study.
        Postgrad Med. 2009; 121: 5-14
        • Dahlof B.
        • Sever P.S.
        • Poulter N.R.
        • et al.
        Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.
        Lancet. 2005; 366: 895-906
        • Kjeldsen S.E.
        • Jamerson K.A.
        • Bakris G.L.
        • et al.
        Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study.
        Blood Press. 2008; 17: 7-17
        • Weber M.A.
        • Bakris G.L.
        • Dahlof B.
        • et al.
        Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk.
        Blood Press. 2007; 16: 13-19
        • Weber M.A.
        • Bakris G.L.
        • Jamerson K.
        • et al.
        Cardiovascular events during differing hypertension therapies in patients with diabetes.
        J Am Coll Cardiol. 2010; 56: 77-85
        • Mancia G.
        • Laurent S.
        • Agabiti-Rosei E.
        • et al.
        Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document.
        J Hypertens. 2009; 27: 2121-2158
        • White W.B.
        • Punzi H.A.
        • Murwin D.
        • et al.
        Effects of the angiotensin II receptor blockers telmisartan vs valsartan in combination with hydrochlorothiazide 25 mg once daily for the treatment of hypertension.
        J Clin Hypertens (Greenwich). 2006; 8: 626-633
        • White W.B.
        • Murwin D.
        • Chrysant S.G.
        • et al.
        Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial.
        Blood Press Monit. 2008; 13: 21-27
        • White W.B.
        • Davidai G.
        • Schumacher H.
        Impact of angiotensin receptor blockade in combination with hydrochlorothiazide 25 mg in 2121 patients with stage 1-2 hypertension.
        J Hum Hypertens. 2009; 23: 817-825
        • Allemann Y.
        • Fraile B.
        • Lambert M.
        • et al.
        Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in Failure after Single Therapy (EX-FAST) study.
        J Clin Hypertens (Greenwich). 2008; 10: 185-194
        • Chrysant S.G.
        • Melino M.
        • Karki S.
        • et al.
        The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study.
        Clin Ther. 2008; 30: 587-604
        • Flack J.M.
        • Hilkert R.
        Single-pill combination of amlodipine and valsartan in the management of hypertension.
        Expert Opin Pharmacother. 2009; 10: 1979-1994
        • McGill J.B.
        • Reilly P.A.
        Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial.
        Clin Ther. 2001; 23: 833-850
        • Kaneshiro Y.
        • Ichihara A.
        • Sakoda M.
        • et al.
        Add-on benefits of amlodipine and thiazide in nondiabetic chronic kidney disease stage 1/2 patients treated with valsartan.
        Kidney Blood Press Res. 2009; 32: 51-58
        • Ichihara A.
        • Kaneshiro Y.
        • Takemitsu T.
        • Sakoda M.
        Effects of amlodipine and valsartan on vascular damage and ambulatory blood pressure in untreated hypertensive patients.
        J Hum Hypertens. 2006; 20: 787-794
        • Mazzolai L.
        • Burnier M.
        Comparative safety and tolerability of angiotensin II receptor antagonists.
        Drug Saf. 1999; 21: 23-33
        • Bangalore S.
        • Kamalakkannan G.
        • Parkar S.
        • Messerli F.H.
        Fixed-dose combinations improve medication compliance: a meta-analysis.
        Am J Med. 2007; 120: 713-719
        • Dickson M.
        • Plauschinat C.A.
        Compliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapy.
        Am J Cardiovasc Drugs. 2008; 8: 45-50
        • Yusuf S.
        • Teo K.K.
        • Pogue J.
        • et al.
        Telmisartan, ramipril, or both in patients at high risk for vascular events.
        N Engl J Med. 2008; 358: 1547-1559
        • FDA Federal Register
        ICH Harmonised Tripartite Guideline for Good Clinical Practice.
        (Accessed February 20, 2011)
        • Pickering T.G.
        • Hall J.E.
        • Appel L.J.
        • et al.
        Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research.
        Hypertension. 2005; 45: 142-161
        • Brown H.
        • Prescott R.
        Applied Mixed Models in Medicine.
        2nd ed. John Wiley & Sons Ltd, Chichester, United Kingdom2006
        • Dmitrienko A.
        • Molenberghs G.
        • Chuang-Stein C.
        Analysis of Clinical Trials Using SAS: A Practical Guide.
        SAS Press, 2005
        • Lewington S.
        • Clarke R.
        • Qizilbash N.
        • et al.
        Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.
        Lancet. 2002; 360: 1903-1913
      1. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
        JAMA. 2002; 288: 2981-2997
        • Julius S.
        • Kjeldsen S.E.
        • Weber M.
        • et al.
        Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.
        Lancet. 2004; 363: 2022-2031
        • Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group
        Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension.
        JAMA. 1991; 265: 3255-3264
        • Staessen J.A.
        • Fagard R.
        • Thijs L.
        • et al.
        • The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators
        Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension.
        Lancet. 1997; 350: 757-764
        • Hansson L.
        • Lindholm L.H.
        • Ekbom T.
        • et al.
        Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study.
        Lancet. 1999; 354: 1751-1756
        • Brown M.J.
        • Palmer C.R.
        • Castaigne A.
        • et al.
        Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT).
        Lancet. 2000; 356: 366-372
        • Flack J.M.
        • Nasser S.A.
        • Levy P.D.
        Therapy of hypertension in African Americans.
        Am J Cardiovasc Drugs. 2011; 11: 83-92
        • Destro M.
        • Luckow A.
        • Samson M.
        • et al.
        Efficacy and safety of amlodipine/valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension: a randomized, double-blind, multicenter study: the EX-EFFeCTS Study.
        J Am Soc Hypertens. 2008; 2: 294-302
        • Lai W.T.
        • Park J.E.
        • Dongre N.
        • Wang J.
        Efficacy, safety, and tolerability of valsartan/hydrochlorothiazide in Asian patients with essential hypertension.
        Adv Ther. 2011; 28: 427-438
        • Huang J.
        • Sun N.L.
        • Hao Y.M.
        • et al.
        Efficacy and tolerability of a single-pill combination of amlodipine/valsartan in Asian hypertensive patients not adequately controlled with valsartan monotherapy.
        Clin Exp Hypertens. 2011; 33: 179-186
        • Ke Y.
        • Zhu D.
        • Hong H.
        • et al.
        Efficacy and safety of a single-pill combination of amlodipine/valsartan in Asian hypertensive patients inadequately controlled with amlodipine monotherapy.
        Curr Med Res Opin. 2010; 26: 1705-1713
        • Kita T.
        • Yokota N.
        • Ichiki Y.
        • et al.
        One-year effectiveness and safety of open-label losartan/hydrochlorothiazide combination therapy in Japanese patients with hypertension uncontrolled with ARBs or ACE inhibitors.
        Hypertens Res. 2010; 33: 320-325
        • Sun N.L.
        • Zhu J.R.
        • Zhao Y.
        • Tu Y.M.
        Combination antihypertensive therapy with valsartan and hydrochlorothiazide in Chinese patients with mild-to-moderate hypertension.
        Curr Med Res Opin. 2008; 24: 2863-2871
        • Schumacher H.
        • Mancia G.
        The safety profile of telmisartan as monotherapy or combined with hydrochlorothiazide: a retrospective analysis of 50 studies.
        Blood Press Suppl. 2008; 1: 32-40